# Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

> **NCT06975644** · NA · NOT_YET_RECRUITING · sponsor: **Zhejiang Provincial People's Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer (TNBC)
- Neoadjuvant Chemotherapy
- Chemotherapy Effects

## Interventions

- **DRUG:** nab-paclitaxel, carboplatin, and bemotuzumab
- **DRUG:** epirubicin, cyclophosphamide, and bemotuzumab

## Key facts

- **NCT ID:** NCT06975644
- **Lead sponsor:** Zhejiang Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975644, "Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06975644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*